midodrine has been researched along with Blood Pressure, Low in 73 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the feasibility and physiological efficacy of adjunctive midodrine in patients with vasopressor-dependent hypotension." | 9.51 | A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study. ( Bellomo, R; Brown, A; Costa-Pinto, R; Eastwood, G; Udy, A; Yanase, F; Yong, ZT; Young, C; Young, PJ, 2022) |
| "Prophylactic administration of 10-mg midodrine tablets before spinal anesthesia is an effective method in the prevention of hypotension in young adult patients undergoing elective orthopedic knee surgery." | 9.51 | Efficacy of Preoperative Oral Midodrine in Preventing Hypotension After Spinal Anesthesia in Young Adults: A Randomized Controlled Trial. ( Abdelsalam, TA; Alseoudy, MM; Nasr, MO, 2022) |
| "Midodrine did not accelerate liberation from intravenous vasopressors and was not effective for the treatment of hypotension in critically ill patients." | 9.34 | Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial. ( Anstey, MH; Eikermann, M; Houle, TT; Parsons, CS; Patrocínio, MD; Santer, P; Shaefi, S; Shay, D; Teja, B; Wibrow, B, 2020) |
| "Cool dialysate and midodrine have been used successfully to treat intradialytic hypotension (IDH) in the end-stage renal disease population." | 9.10 | Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. ( Abu-Alfa, AK; Hoeben, H; Mahnensmith, R; Perazella, MA, 2002) |
| "Midodrine lessens the fall in arterial pressure during hemodialysis, in patients with symptomatic hypotension." | 9.10 | [Effects of midodrine on symptomatic hypotension during hemodialysis]. ( Alvo, M; Cotera, A; Cuadra, C; Elgueta, L; Gormaz, JP; Ibáñez, C; Sanhueza, ME, 2002) |
| "We describe a man in his 40s with a history of chronic intranasal cocaine use and C5-C7 incomplete quadriplegia complicated by neurogenic orthostatic hypotension, admitted to the intensive care unit for worsening bradycardia and hypotension requiring initiation of dopamine and an increase of his home midodrine dose." | 8.31 | Refractory bradycardia and hypotension in patients with autonomic dysfunction treated with pseudoephedrine. ( Curran, C; Davoudi, F; Foster, G; Gordan, P, 2023) |
| " After the procedure, he developed prolonged post-carotid artery stenting hypotension, which was resistant to intravenous fluids and inotropes but immediately showed a promising response to oral midodrine." | 8.12 | Treatment via oral midodrine in a patient with prolonged hypotension following carotid artery stenting: a case report. ( Abtahi-Eivary, SM; Hosseini, K; Jenab, Y, 2022) |
| "Midodrine is widely used in the treatment of hypotensive states, there have been no reports of myoclonus associated with midodrine use in hypotension with chronic kidney disease." | 7.96 | Case report: severe myoclonus associated with oral midodrine treatment for hypotension. ( Chen, M; Ling, B; Ren, Y; Song, F; Wu, J; Wu, S; Xuan, Z; Ye, X; Zhang, H, 2020) |
| "A 49-year-old patient tolerated 60-mg daily doses of midodrine along with 30-mg intradialytic doses for the management of treprostinil-induced hypotension and prevention of HD interruption, without adverse effects." | 7.91 | Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis. ( Alobaidi, A; Bielnicka, P; Drambarean, B, 2019) |
| " We report a case of ingestion of topical minoxidil [Rogaine® (Johnson & Johnson Healthcare Products, Division of McNeil-PPC, Inc)] resulting in refractory hypotension that was successfully managed with the oral α (1) agonist midodrine." | 7.77 | Refractory hypotension due to Rogaine® (minoxidil) ingestion managed with midodrine. ( Aaronson, P; Garrard, A; Sollee, D; Wood, A, 2011) |
| "Outpatient dialysis is possible and relieves the symptoms of congestive heart failure in patients with poor heart function, low blood pressure, and advanced age when midodrine is given immediately before and during the procedure." | 7.75 | Hemodialysis in hypotensive heart failure using midodrine. ( Bergman, SM, 2009) |
| "Midodrine improves chronic hypotension in HD patients by modulating autonomic function and its direct effects on peripheral vessels." | 7.72 | Midodrine improves chronic hypotension in hemodialysis patients. ( Denq, JC; Lin, SH; Lin, YF; Wang, JY, 2003) |
| " Although a beta blocker was not effective in preventing tilt-induced hypotension and bradycardia, midodrine hydrochloride (alpha-1 stimulant) or atropine prevented it." | 7.68 | A case of vasovagal syncope with convulsions--the effects of midodrine hydrochloride. ( Aizawa, Y; Igarashi, Y; Izumi, T; Koyama, S; Matsubara, T; Ohshima, M; Tamura, Y; Yamaguchi, T; Yamazaki, Y; Yamazoe, M, 1992) |
| "Midodrine appears to be an effective and safe treatment for HD patients with symptomatic IDH, and remains beneficial when used for an extended period of time." | 6.69 | Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. ( Brickel, HM; Cruz, DN; Mahnensmith, RL; Perazella, MA, 1998) |
| "Midodrine treatment also significantly increased postdialysis systolic and diastolic blood pressures from baseline values of 90." | 6.68 | Midodrine for the treatment of intradialytic hypotension. ( Li, HP; Lim, PS; Lim, YT; Yang, CC; Yeh, CH, 1997) |
| "Oral midodrine appears to be a safe and effective therapy for the treatment of hemodialysis hypotension." | 6.68 | Midodrine treatment for patients with hemodialysis hypotension. ( Caruso, FS; Flynn, JJ; McElligott, MA; Mitchell, MC, 1996) |
| " The effective oral dosage in infancy and childhood is 0." | 6.65 | [Infectious toxic hypotension--effect and dosage of midodrine (author's transl)]. ( Weippl, G, 1979) |
| "Midodrine is an oral, peripherally acting alpha-adrenergic agonist." | 6.55 | The Role of Midodrine for Hypotension Outside of the Intensive Care Unit. ( Gutman, LB; Wilson, BJ, 2017) |
| "Dialysis-induced hypotension is an important complication of haemodialysis." | 6.42 | Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. ( Garg, AX; Heidenheim, AP; House, AA; Prakash, S, 2004) |
| " This medication has been demonstrated to be effective and safe in the acute and chronic treatment of haemodialysis-associated hypotension in end stage renal disease patients." | 6.42 | Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension. ( Perazella, MA, 2003) |
| " Midodrine is a prodrug that is almost completely absorbed after oral administration and converted into its active drug de-glymidodrine in the systematic circulation, with a bioavailability of 93%." | 6.41 | Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. ( Cruz, DN, 2000) |
| "Midodrine was started as a last resort attempt to wean off vasopressors." | 5.91 | Midodrine in end-stage heart failure. ( Franqui-Rivera, H; Gonzalez-Cordero, A; Mesa-Pabón, M; Nieves-Rivera, J; Ortiz-Troche, S, 2023) |
| "Midodrine (10 mg) administered in the home environment effectively increases BP and reduces the incidence of hypotension; however these beneficial effects come at the expense of worsened BP instability and AD symptom intensity." | 5.69 | Clinical trial of home blood pressure monitoring following midodrine administration in hypotensive individuals with spinal cord injury. ( Bauman, WA; Dyson-Hudson, TA; Katzelnick, CG; Kirshblum, SC; Wecht, JM; Weir, JP, 2023) |
| "Prophylactic administration of 10-mg midodrine tablets before spinal anesthesia is an effective method in the prevention of hypotension in young adult patients undergoing elective orthopedic knee surgery." | 5.51 | Efficacy of Preoperative Oral Midodrine in Preventing Hypotension After Spinal Anesthesia in Young Adults: A Randomized Controlled Trial. ( Abdelsalam, TA; Alseoudy, MM; Nasr, MO, 2022) |
| "To assess the feasibility and physiological efficacy of adjunctive midodrine in patients with vasopressor-dependent hypotension." | 5.51 | A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study. ( Bellomo, R; Brown, A; Costa-Pinto, R; Eastwood, G; Udy, A; Yanase, F; Yong, ZT; Young, C; Young, PJ, 2022) |
| "Hypotension is commonly encountered during carotid artery stenting (CAS), mediated by vagal stimulation and suppression of sympathetic outflow." | 5.35 | Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting. ( Bhambi, B; Lardizabal, JA; Sharma, S, 2008) |
| "Midodrine did not accelerate liberation from intravenous vasopressors and was not effective for the treatment of hypotension in critically ill patients." | 5.34 | Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial. ( Anstey, MH; Eikermann, M; Houle, TT; Parsons, CS; Patrocínio, MD; Santer, P; Shaefi, S; Shay, D; Teja, B; Wibrow, B, 2020) |
| "We used the oral agent midodrine to treat hypotension that complicated myocardial stunning after successful revascularization with percutaneous coronary intervention in the setting of myocardial infarction and ischemia." | 5.33 | Successful treatment of hypotension associated with stunned myocardium with oral midodrine therapy. ( Bhambi, B; Sharma, S, 2005) |
| "Other than scalp paresthesia in one patient, no adverse effects were noted." | 5.30 | Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? ( Cruz, DN; Mahnensmith, RL; Perazella, MA, 1997) |
| "Midodrine hydrochloride was administered at a dose of 2." | 5.29 | Midodrine hydrochloride in patients on hemodialysis with chronic hypotension. ( Fang, JT; Huang, CC, 1996) |
| " The pharmacokinetic characteristics of the prodrug midodrine and the active metabolite de-glymidodrine in this patient with end-stage renal disease approximate those reported for patients with normal renal function." | 5.29 | Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. ( Balfe, JW; Blowey, DL; Gajaria, MM; Gupta, I; Koren, G, 1996) |
| "These findings suggest that midodrine 10mg may be efficacious for treatment of hypotension and orthostatic hypotension in select persons with tetraplegia." | 5.14 | Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. ( Bauman, WA; Handrakis, JP; Radulovic, M; Rosado-Rivera, D; Wecht, JM, 2010) |
| "Cool dialysate and midodrine have been used successfully to treat intradialytic hypotension (IDH) in the end-stage renal disease population." | 5.10 | Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. ( Abu-Alfa, AK; Hoeben, H; Mahnensmith, R; Perazella, MA, 2002) |
| "Midodrine lessens the fall in arterial pressure during hemodialysis, in patients with symptomatic hypotension." | 5.10 | [Effects of midodrine on symptomatic hypotension during hemodialysis]. ( Alvo, M; Cotera, A; Cuadra, C; Elgueta, L; Gormaz, JP; Ibáñez, C; Sanhueza, ME, 2002) |
| "We describe a man in his 40s with a history of chronic intranasal cocaine use and C5-C7 incomplete quadriplegia complicated by neurogenic orthostatic hypotension, admitted to the intensive care unit for worsening bradycardia and hypotension requiring initiation of dopamine and an increase of his home midodrine dose." | 4.31 | Refractory bradycardia and hypotension in patients with autonomic dysfunction treated with pseudoephedrine. ( Curran, C; Davoudi, F; Foster, G; Gordan, P, 2023) |
| " After the procedure, he developed prolonged post-carotid artery stenting hypotension, which was resistant to intravenous fluids and inotropes but immediately showed a promising response to oral midodrine." | 4.12 | Treatment via oral midodrine in a patient with prolonged hypotension following carotid artery stenting: a case report. ( Abtahi-Eivary, SM; Hosseini, K; Jenab, Y, 2022) |
| "Midodrine is widely used in the treatment of hypotensive states, there have been no reports of myoclonus associated with midodrine use in hypotension with chronic kidney disease." | 3.96 | Case report: severe myoclonus associated with oral midodrine treatment for hypotension. ( Chen, M; Ling, B; Ren, Y; Song, F; Wu, J; Wu, S; Xuan, Z; Ye, X; Zhang, H, 2020) |
| "A 49-year-old patient tolerated 60-mg daily doses of midodrine along with 30-mg intradialytic doses for the management of treprostinil-induced hypotension and prevention of HD interruption, without adverse effects." | 3.91 | Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis. ( Alobaidi, A; Bielnicka, P; Drambarean, B, 2019) |
| "Midodrine is an α1-agonist approved for orthostatic hypotension." | 3.91 | Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study. ( Barreto, EF; Gajic, O; Mara, KC; Nei, AM; Rizvi, MS, 2019) |
| "Midodrine is prescribed to prevent symptomatic hypotension and decrease complications associated with hypotension during dialysis." | 3.83 | Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications After Kidney Transplantation. ( Alhamad, T; Axelrod, D; Brennan, DC; Brifkani, Z; Dharnidharka, VR; Lentine, KL; Schnitzler, MA; Segev, DL; Xiao, H, 2016) |
| " We report a case of ingestion of topical minoxidil [Rogaine® (Johnson & Johnson Healthcare Products, Division of McNeil-PPC, Inc)] resulting in refractory hypotension that was successfully managed with the oral α (1) agonist midodrine." | 3.77 | Refractory hypotension due to Rogaine® (minoxidil) ingestion managed with midodrine. ( Aaronson, P; Garrard, A; Sollee, D; Wood, A, 2011) |
| "Outpatient dialysis is possible and relieves the symptoms of congestive heart failure in patients with poor heart function, low blood pressure, and advanced age when midodrine is given immediately before and during the procedure." | 3.75 | Hemodialysis in hypotensive heart failure using midodrine. ( Bergman, SM, 2009) |
| "Fludrocortisone is recommended in patients with orthostatic hypotension and a benefit has been suggested in hemodialysis patients with severe hypokaliemia." | 3.73 | Effect of mineralocorticoids on interdialytic weight gain in hemodialysis patients with perdialytic hypotension. ( Mercadal, L; Petitclerc, T, 2005) |
| "Midodrine improves chronic hypotension in HD patients by modulating autonomic function and its direct effects on peripheral vessels." | 3.72 | Midodrine improves chronic hypotension in hemodialysis patients. ( Denq, JC; Lin, SH; Lin, YF; Wang, JY, 2003) |
| "In order to treat postprandial hypotension (PPH), we orally administered a combination of denopamine (10 mg, a selective beta 1-adrenergic agonist) and midodrine-HCl (4 mg, a selective alpha 1-adrenergic agonist) to eight patients with autonomic failure (AF) prior to and after eating." | 3.68 | Treatment of postprandial hypotension with selective alpha 1 and beta 1 adrenergic agonists. ( Hakusui, S; Hirayama, M; Kaneoke, Y; Koike, Y; Sakurai, N; Takahashi, A; Watanabe, H, 1993) |
| " Although a beta blocker was not effective in preventing tilt-induced hypotension and bradycardia, midodrine hydrochloride (alpha-1 stimulant) or atropine prevented it." | 3.68 | A case of vasovagal syncope with convulsions--the effects of midodrine hydrochloride. ( Aizawa, Y; Igarashi, Y; Izumi, T; Koyama, S; Matsubara, T; Ohshima, M; Tamura, Y; Yamaguchi, T; Yamazaki, Y; Yamazoe, M, 1992) |
| "However, treatment of hypotension is uncommon in the SCI population because there are few safe and effective pharmacological options available." | 2.94 | Double-blinded, placebo-controlled crossover trial to determine the effects of midodrine on blood pressure during cognitive testing in persons with SCI. ( Bauman, WA; Chiaravalloti, ND; Dyson-Hudson, TA; Katzelnick, CG; Kirshblum, SC; Weber, E; Wecht, JM; Weir, JP, 2020) |
| "Midodrine is an oral α 1-adrenergic receptor agonist that offers a potential means of liberating patients from IV vasopressor therapy." | 2.82 | Putting midodrine on the MAP: An approach to liberation from intravenous vasopressors in vasodilatory shock. ( Floris, LM; Hawkins, WA; Patterson, JM; Peters, NA; Smith, SE, 2022) |
| "Chronic low blood pressure is typically accompanied with symptoms such as fatigue, reduced drive, dizziness, headaches and cold limbs." | 2.74 | Modulations of autonomic cardiovascular control following acute alpha-adrenergic treatment in chronic hypotension. ( Duschek, S; Heiss, H; Reyes del Paso, GA; Werner, N, 2009) |
| "Chronic low blood pressure is typically accompanied by symptoms such as fatigue, reduced drive, dizziness, headaches and cold limbs." | 2.74 | Hemodynamic determinants of chronic hypotension and their modification through vasopressor application. ( Buechner, B; Duschek, S; Heiss, H; Reyes del Paso, GA; Schandry, R; Werner, N, 2009) |
| "If cardiac syncope is unlikely, reflex (neurally mediated) syncope and orthostatic hypotension are the most frequent causes of transient loss of consciousness." | 2.72 | New insights in diagnostics and therapies in syncope: a novel approach to non-cardiac syncope. ( Brignole, M; Rivasi, G, 2021) |
| "Midodrine appears to be an effective and safe treatment for HD patients with symptomatic IDH, and remains beneficial when used for an extended period of time." | 2.69 | Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. ( Brickel, HM; Cruz, DN; Mahnensmith, RL; Perazella, MA, 1998) |
| "Oral midodrine appears to be a safe and effective therapy for the treatment of hemodialysis hypotension." | 2.68 | Midodrine treatment for patients with hemodialysis hypotension. ( Caruso, FS; Flynn, JJ; McElligott, MA; Mitchell, MC, 1996) |
| "Midodrine treatment also significantly increased postdialysis systolic and diastolic blood pressures from baseline values of 90." | 2.68 | Midodrine for the treatment of intradialytic hypotension. ( Li, HP; Lim, PS; Lim, YT; Yang, CC; Yeh, CH, 1997) |
| "Midodrine is an orally administered alpha-1 adrenergic agonist while methylene blue is an intravenously administered blue dye used to restore vascular tone and increase blood pressure." | 2.66 | Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock. ( Sullivan, JB; Tchen, S, 2020) |
| "5 mg midodrine tablets and dosage was adjusted according to each patient's condition." | 2.65 | Controlled clinical investigation of dimetophrine versus midodrine in the management of moderately decreased arterial blood pressure. ( Cecchi, A; Marini, U; Venturini, M, 1984) |
| " The effective oral dosage in infancy and childhood is 0." | 2.65 | [Infectious toxic hypotension--effect and dosage of midodrine (author's transl)]. ( Weippl, G, 1979) |
| "Midodrine is an oral, peripherally acting alpha-adrenergic agonist." | 2.55 | The Role of Midodrine for Hypotension Outside of the Intensive Care Unit. ( Gutman, LB; Wilson, BJ, 2017) |
| " This medication has been demonstrated to be effective and safe in the acute and chronic treatment of haemodialysis-associated hypotension in end stage renal disease patients." | 2.42 | Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension. ( Perazella, MA, 2003) |
| "Dialysis-induced hypotension is an important complication of haemodialysis." | 2.42 | Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. ( Garg, AX; Heidenheim, AP; House, AA; Prakash, S, 2004) |
| " Midodrine is a prodrug that is almost completely absorbed after oral administration and converted into its active drug de-glymidodrine in the systematic circulation, with a bioavailability of 93%." | 2.41 | Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. ( Cruz, DN, 2000) |
| "Midodrine was started as a last resort attempt to wean off vasopressors." | 1.91 | Midodrine in end-stage heart failure. ( Franqui-Rivera, H; Gonzalez-Cordero, A; Mesa-Pabón, M; Nieves-Rivera, J; Ortiz-Troche, S, 2023) |
| "Arterial hypotension is a frequently encountered phenomenon in clinical practice." | 1.48 | [Arterial hypotension: behind the scenes]. ( Pechere-Bertschi, A; Roukain, A, 2018) |
| "Midodrine treatment was associated with an increase in the magnitude of decline of the IV vasopressor rate." | 1.39 | Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. ( Ball, SA; Berg, S; Bittner, EA; Eikermann, M; Kalman, R; Levine, AR; Meyer, MJ; Ryan, C; Stanislaus, AB, 2013) |
| "Hypotension is commonly encountered during carotid artery stenting (CAS), mediated by vagal stimulation and suppression of sympathetic outflow." | 1.35 | Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting. ( Bhambi, B; Lardizabal, JA; Sharma, S, 2008) |
| "We used the oral agent midodrine to treat hypotension that complicated myocardial stunning after successful revascularization with percutaneous coronary intervention in the setting of myocardial infarction and ischemia." | 1.33 | Successful treatment of hypotension associated with stunned myocardium with oral midodrine therapy. ( Bhambi, B; Sharma, S, 2005) |
| "Other than scalp paresthesia in one patient, no adverse effects were noted." | 1.30 | Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? ( Cruz, DN; Mahnensmith, RL; Perazella, MA, 1997) |
| "Midodrine hydrochloride was administered at a dose of 2." | 1.29 | Midodrine hydrochloride in patients on hemodialysis with chronic hypotension. ( Fang, JT; Huang, CC, 1996) |
| " The pharmacokinetic characteristics of the prodrug midodrine and the active metabolite de-glymidodrine in this patient with end-stage renal disease approximate those reported for patients with normal renal function." | 1.29 | Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. ( Balfe, JW; Blowey, DL; Gajaria, MM; Gupta, I; Koren, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (9.59) | 18.7374 |
| 1990's | 12 (16.44) | 18.2507 |
| 2000's | 23 (31.51) | 29.6817 |
| 2010's | 14 (19.18) | 24.3611 |
| 2020's | 17 (23.29) | 2.80 |
| Authors | Studies |
|---|---|
| Costa-Pinto, R | 1 |
| Yong, ZT | 1 |
| Yanase, F | 1 |
| Young, C | 1 |
| Brown, A | 1 |
| Udy, A | 1 |
| Young, PJ | 1 |
| Eastwood, G | 1 |
| Bellomo, R | 1 |
| Jenab, Y | 1 |
| Hosseini, K | 1 |
| Abtahi-Eivary, SM | 1 |
| Smith, SE | 1 |
| Peters, NA | 1 |
| Floris, LM | 1 |
| Patterson, JM | 1 |
| Hawkins, WA | 1 |
| Alseoudy, MM | 1 |
| Nasr, MO | 1 |
| Abdelsalam, TA | 1 |
| Wecht, JM | 3 |
| Weir, JP | 2 |
| Katzelnick, CG | 2 |
| Dyson-Hudson, TA | 2 |
| Bauman, WA | 3 |
| Kirshblum, SC | 2 |
| House, AA | 2 |
| McIntyre, CW | 1 |
| Husarek, K | 1 |
| Brunelli, SM | 2 |
| Kim, JP | 1 |
| Chang, TI | 1 |
| Curran, C | 1 |
| Davoudi, F | 1 |
| Foster, G | 1 |
| Gordan, P | 1 |
| Tchen, S | 1 |
| Sullivan, JB | 1 |
| Chiaravalloti, ND | 1 |
| Weber, E | 1 |
| Gonzalez-Cordero, A | 1 |
| Ortiz-Troche, S | 1 |
| Nieves-Rivera, J | 1 |
| Mesa-Pabón, M | 1 |
| Franqui-Rivera, H | 1 |
| Santer, P | 2 |
| Anstey, MH | 1 |
| Patrocínio, MD | 1 |
| Wibrow, B | 1 |
| Teja, B | 1 |
| Shay, D | 1 |
| Shaefi, S | 1 |
| Parsons, CS | 1 |
| Houle, TT | 1 |
| Eikermann, M | 3 |
| Ye, X | 1 |
| Ling, B | 1 |
| Wu, J | 1 |
| Wu, S | 1 |
| Ren, Y | 1 |
| Zhang, H | 1 |
| Song, F | 1 |
| Xuan, Z | 1 |
| Chen, M | 1 |
| Riker, RR | 1 |
| Gagnon, DJ | 1 |
| Brignole, M | 1 |
| Rivasi, G | 1 |
| Gutman, LB | 1 |
| Wilson, BJ | 1 |
| Roukain, A | 1 |
| Pechere-Bertschi, A | 1 |
| Cohen, DE | 1 |
| Marlowe, G | 1 |
| Van Wyck, D | 1 |
| Hammes, M | 1 |
| Bakris, GL | 1 |
| Raina, R | 1 |
| Lam, S | 1 |
| Raheja, H | 1 |
| Krishnappa, V | 1 |
| Hothi, D | 1 |
| Davenport, A | 1 |
| Chand, D | 1 |
| Kapur, G | 1 |
| Schaefer, F | 1 |
| Sethi, SK | 1 |
| McCulloch, M | 1 |
| Bagga, A | 1 |
| Bunchman, T | 1 |
| Warady, BA | 1 |
| Rizvi, MS | 1 |
| Nei, AM | 1 |
| Gajic, O | 1 |
| Mara, KC | 1 |
| Barreto, EF | 1 |
| Drambarean, B | 1 |
| Bielnicka, P | 1 |
| Alobaidi, A | 1 |
| Levine, AR | 1 |
| Meyer, MJ | 1 |
| Bittner, EA | 1 |
| Berg, S | 1 |
| Kalman, R | 1 |
| Stanislaus, AB | 1 |
| Ryan, C | 1 |
| Ball, SA | 1 |
| Phillips, AA | 1 |
| Warburton, DE | 1 |
| Ainslie, PN | 1 |
| Krassioukov, AV | 1 |
| Tanabe, N | 1 |
| Takane, K | 1 |
| Yokoyama, K | 1 |
| Tanno, Y | 1 |
| Yamamoto, I | 1 |
| Ohkido, I | 1 |
| Yokoo, T | 1 |
| Alhamad, T | 1 |
| Brennan, DC | 1 |
| Brifkani, Z | 1 |
| Xiao, H | 1 |
| Schnitzler, MA | 1 |
| Dharnidharka, VR | 1 |
| Axelrod, D | 1 |
| Segev, DL | 1 |
| Lentine, KL | 1 |
| Hothi, DK | 1 |
| Harvey, E | 1 |
| Goia, CM | 1 |
| Geary, D | 1 |
| Newton, JL | 1 |
| Sheth, A | 1 |
| Shin, J | 1 |
| Pairman, J | 1 |
| Wilton, K | 1 |
| Burt, JA | 1 |
| Jones, DE | 1 |
| Duschek, S | 2 |
| Heiss, H | 2 |
| Buechner, B | 1 |
| Werner, N | 2 |
| Schandry, R | 1 |
| Reyes del Paso, GA | 2 |
| Parati, G | 1 |
| Di Rienzo, M | 1 |
| Coruzzi, P | 1 |
| Castiglioni, P | 1 |
| Bergman, SM | 1 |
| Rosado-Rivera, D | 1 |
| Handrakis, JP | 1 |
| Radulovic, M | 1 |
| Garrard, A | 1 |
| Wood, A | 1 |
| Sollee, D | 1 |
| Aaronson, P | 1 |
| Hassinger, AB | 1 |
| Garimella, S | 1 |
| Cotera, A | 1 |
| Alvo, M | 1 |
| Sanhueza, ME | 1 |
| Elgueta, L | 1 |
| Gormaz, JP | 1 |
| Ibáñez, C | 1 |
| Cuadra, C | 1 |
| O'Donnell, B | 1 |
| Synnott, A | 1 |
| Lin, YF | 1 |
| Wang, JY | 1 |
| Denq, JC | 1 |
| Lin, SH | 1 |
| Perazella, MA | 7 |
| Schrage, WG | 1 |
| Eisenach, JH | 1 |
| Dinenno, FA | 1 |
| Roberts, SK | 1 |
| Johnson, CP | 1 |
| Sandroni, P | 1 |
| Low, PA | 1 |
| Joyner, MJ | 1 |
| Prakash, S | 1 |
| Garg, AX | 1 |
| Heidenheim, AP | 1 |
| Maule, S | 1 |
| Tredici, M | 1 |
| Dematteis, A | 1 |
| Matteoda, C | 1 |
| Chiandussi, L | 1 |
| Sharma, S | 2 |
| Bhambi, B | 2 |
| Mercadal, L | 1 |
| Petitclerc, T | 1 |
| Lardizabal, JA | 1 |
| Hebenstreit, G | 1 |
| Marini, U | 1 |
| Cecchi, A | 1 |
| Venturini, M | 1 |
| Hirayama, M | 3 |
| Watanabe, H | 2 |
| Koike, Y | 3 |
| Kaneoke, Y | 2 |
| Sakurai, N | 1 |
| Hakusui, S | 1 |
| Takahashi, A | 3 |
| Blowey, DL | 1 |
| Balfe, JW | 1 |
| Gupta, I | 1 |
| Gajaria, MM | 1 |
| Koren, G | 1 |
| Fang, JT | 1 |
| Huang, CC | 1 |
| Flynn, JJ | 1 |
| Mitchell, MC | 1 |
| Caruso, FS | 1 |
| McElligott, MA | 1 |
| Lim, PS | 1 |
| Yang, CC | 1 |
| Li, HP | 1 |
| Lim, YT | 1 |
| Yeh, CH | 1 |
| Cruz, DN | 4 |
| Mahnensmith, RL | 3 |
| Brickel, HM | 2 |
| Izhar, M | 1 |
| Montagnac, R | 2 |
| Clavel, P | 2 |
| Delhotal-Landes, B | 2 |
| Flouvat, B | 2 |
| Poulain, S | 2 |
| Schillinger, F | 1 |
| Alappan, R | 1 |
| Cruz, D | 1 |
| Abu-Alfa, AK | 2 |
| Mahnensmith, R | 2 |
| Ieda, T | 1 |
| Sobue, G | 1 |
| Schllinger, F | 1 |
| Hoeben, H | 1 |
| Lacbnit, VK | 1 |
| Kiesewetter, E | 1 |
| Deimer, E | 1 |
| Fischer, M | 1 |
| Höcker, P | 1 |
| Mermon, R | 1 |
| Mostbeck, A | 1 |
| Pittner, H | 3 |
| Witek, F | 1 |
| Stormann, H | 1 |
| Enzenhofer, R | 1 |
| Sazovsky, H | 1 |
| Weippl, G | 1 |
| Dabasaki, T | 1 |
| Shimojo, M | 1 |
| Ishikawa, H | 1 |
| Uemura, A | 1 |
| Koyama, S | 1 |
| Matsubara, T | 1 |
| Aizawa, Y | 1 |
| Ohshima, M | 1 |
| Yamaguchi, T | 1 |
| Yamazaki, Y | 1 |
| Igarashi, Y | 1 |
| Tamura, Y | 1 |
| Yamazoe, M | 1 |
| Izumi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preoperative Midodrine for Improving Hemodynamics in Orthopedic Patients Undergoing Spinal Anesthesia[NCT04396548] | 70 participants (Actual) | Interventional | 2020-06-08 | Completed | |||
| RANDOMIZED CASE-CONTROLLED TRIAL ASSESSING MIDODRINE (GUTRON®) IN POSTOPERATIVE VASOPLEGIC PATIENTS[NCT04440085] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-09-14 | Not yet recruiting | ||
| Blood Pressure, Cerebral Blood Flow and Cognition in SCI[NCT02307565] | Phase 3 | 60 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Assessment of the Mechanism of Non-cardiac Syncope by 24-hour Ambulatory Blood Pressure Monitoring (ABPM) and Tilt-table Short Cardiovascular Autonomic Function Battery (SCAFB)[NCT05728255] | 275 participants (Anticipated) | Observational | 2023-04-30 | Not yet recruiting | |||
| Restoring Hemodynamic Stability Using Targeted Epidural Spinal Stimulation Following Spinal Cord Injury[NCT04994886] | 8 participants (Anticipated) | Interventional | 2021-06-08 | Recruiting | |||
| Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury[NCT03602014] | Phase 4 | 22 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| The Effects of Spinal Cord Stimulation on Autonomic Function in People With Spinal Cord Injury[NCT03924388] | 46 participants (Anticipated) | Interventional | 2020-02-01 | Not yet recruiting | |||
| Restoring Hemodynamic Stability Using Targeted Epidural Spinal Stimulation Following Spinal Cord Injury[NCT05044923] | 8 participants (Anticipated) | Interventional | 2021-12-31 | Recruiting | |||
| Epidural Electrical Stimulation to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury[NCT05111093] | 20 participants (Anticipated) | Interventional | 2021-11-29 | Recruiting | |||
| A Dose Response Trial Using 5 and 10 mg. of Midodrine Hydrochloride to Treat Orthostatic Hypotension in Persons With SCI[NCT00426842] | Phase 2 | 11 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Hemodynamic Effects of Low vs. High Dialysate Temperature or Bicarbonate Concentration in Chronic Hemodialysis Patients[NCT05052151] | 16 participants (Actual) | Interventional | 2021-08-25 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
brachial artery systolic blood pressure (mmHg) (NCT00426842)
Timeframe: The difference between the average supine systolic blood pressure and the average systolic blood pressure at 45 degree head-up tilt position.
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline Blood Pressure | Head-up Tilt Blood Pressure | |
| Midodrine 10 mg | 102 | 109 |
| Midodrine 5 mg | 97 | 96 |
| No-drug | 98 | 87 |
8 reviews available for midodrine and Blood Pressure, Low
| Article | Year |
|---|---|
Putting midodrine on the MAP: An approach to liberation from intravenous vasopressors in vasodilatory shock.
Topics: Administration, Intravenous; Adult; Humans; Hypotension; Intensive Care Units; Midodrine; Multicente | 2022 |
Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock.
Topics: Blood Pressure; Catecholamines; Critical Care; Critical Illness; Humans; Hypotension; Intensive Care | 2020 |
New insights in diagnostics and therapies in syncope: a novel approach to non-cardiac syncope.
Topics: Accidental Falls; Adenosine; Antihypertensive Agents; Atomoxetine Hydrochloride; Atrioventricular No | 2021 |
The Role of Midodrine for Hypotension Outside of the Intensive Care Unit.
Topics: Adrenergic alpha-Agonists; Humans; Hypotension; Intensive Care Units; Midodrine; Prodrugs; Pruritus | 2017 |
Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension.
Topics: Animals; Attitude of Health Personnel; Blood Pressure; Comorbidity; Humans; Hypotension; Midodrine; | 2003 |
Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review.
Topics: Adrenergic alpha-Agonists; Humans; Hypotension; Midodrine; Renal Dialysis; Treatment Outcome | 2004 |
Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension.
Topics: Adrenergic alpha-Agonists; Humans; Hypotension; Hypotension, Orthostatic; Midodrine; Renal Dialysis | 2000 |
Pharmacologic options available to treat symptomatic intradialytic hypotension.
Topics: Adrenergic Agents; Autonomic Nervous System; Caffeine; Carnitine; Ephedrine; Fludrocortisone; Hemodi | 2001 |
23 trials available for midodrine and Blood Pressure, Low
| Article | Year |
|---|---|
A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study.
Topics: Critical Care; Feasibility Studies; Humans; Hypotension; Midodrine; Vasoconstrictor Agents | 2022 |
Efficacy of Preoperative Oral Midodrine in Preventing Hypotension After Spinal Anesthesia in Young Adults: A Randomized Controlled Trial.
Topics: Anesthesia, Spinal; Bupivacaine; Double-Blind Method; Ephedrine; Fentanyl; Humans; Hypotension; Mido | 2022 |
Clinical trial of home blood pressure monitoring following midodrine administration in hypotensive individuals with spinal cord injury.
Topics: Autonomic Dysreflexia; Blood Pressure Monitoring, Ambulatory; Humans; Hypotension; Hypotension, Orth | 2023 |
Double-blinded, placebo-controlled crossover trial to determine the effects of midodrine on blood pressure during cognitive testing in persons with SCI.
Topics: Adult; Blood Pressure; Cerebrovascular Circulation; Chronic Disease; Cognition; Cross-Over Studies; | 2020 |
Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.
Topics: Adult; Australia; Humans; Hypotension; Intensive Care Units; Midodrine; Vasoconstrictor Agents | 2020 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.
Topics: Adolescent; Adrenergic alpha-1 Receptor Agonists; Adult; Blood Flow Velocity; Cerebrovascular Circul | 2014 |
Lower ambulatory blood pressure in chronic fatigue syndrome.
Topics: Blood Pressure Monitoring, Ambulatory; Fatigue Syndrome, Chronic; Female; Heart Rate; Humans; Hypote | 2009 |
Hemodynamic determinants of chronic hypotension and their modification through vasopressor application.
Topics: Adult; Blood Pressure; Body Height; Body Mass Index; Cardiac Output; Chronic Disease; Double-Blind M | 2009 |
Modulations of autonomic cardiovascular control following acute alpha-adrenergic treatment in chronic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Autonomic Nervous System; Baroreflex; Blood Pressure; Chronic Dise | 2009 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
[Effects of midodrine on symptomatic hypotension during hemodialysis].
Topics: Adrenergic alpha-Agonists; Blood Pressure; Double-Blind Method; Female; Humans; Hypotension; Male; M | 2002 |
Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure.
Topics: Adrenergic alpha-Agonists; Aged; Autonomic Nervous System Diseases; Bicycling; Blood Pressure; Cardi | 2004 |
[Treatment of hypotension caused by psychopharmacological drugs (author's transl)].
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Blood Pressure; Double-Blind Method; Ethanolamin | 1981 |
Controlled clinical investigation of dimetophrine versus midodrine in the management of moderately decreased arterial blood pressure.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Ethanolamines; Female; Heart Rate; Humans; Hy | 1984 |
Midodrine treatment for patients with hemodialysis hypotension.
Topics: Adrenergic alpha-Agonists; Aged; Blood Pressure; Female; Humans; Hypotension; Kidney Failure, Chroni | 1996 |
Midodrine for the treatment of intradialytic hypotension.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Body Weight; Female; H | 1997 |
Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Topics: Adrenergic alpha-Agonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypotension; Kid | 1998 |
Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cold Temperature; Combined Modality Therapy; Cross-Over Stu | 1999 |
Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate.
Topics: Blood Pressure; Calcium; Female; Hemodialysis Solutions; Humans; Hypotension; Kidney Failure, Chroni | 2001 |
[A one-month combined use of selective adrenergic beta 1- and alpha 1-agonists for postprandial hypotension in patients with autonomic failure].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aged; Autonomic Nervous System Diseases; Chroni | 2000 |
Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Blood Volume; Cardiac Output; Cold Temperatu | 2002 |
[Infectious toxic hypotension--effect and dosage of midodrine (author's transl)].
Topics: Bacterial Infections; Blood Pressure; Child; Child, Preschool; Clinical Trials as Topic; Drug Evalua | 1979 |
[Effect of combined therapy with selective beta 1- and alpha 1-adrenergic agonists upon postprandial hypotension in patients with progressive autonomic failure].
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adult; Autonomic Nervous | 1992 |
42 other studies available for midodrine and Blood Pressure, Low
| Article | Year |
|---|---|
Treatment via oral midodrine in a patient with prolonged hypotension following carotid artery stenting: a case report.
Topics: Aged, 80 and over; Carotid Arteries; Carotid Stenosis; Humans; Hypotension; Male; Midodrine; Stents | 2022 |
Midodrine Is an Effective Therapy for Resistant Intradialytic Hypotension: PRO.
Topics: Humans; Hypotension; Midodrine; Renal Dialysis | 2023 |
Midodrine Is an Effective Therapy for Resistant Intradialytic Hypotension: CON.
Topics: Humans; Hypotension; Midodrine; Renal Dialysis | 2023 |
Midodrine Is an Effective Therapy for Resistant Intradialytic Hypotension: COMMENTARY.
Topics: Humans; Hypotension; Midodrine; Renal Dialysis | 2023 |
Refractory bradycardia and hypotension in patients with autonomic dysfunction treated with pseudoephedrine.
Topics: Autonomic Nervous System Diseases; Bradycardia; Dopamine; Humans; Hypotension; Hypotension, Orthosta | 2023 |
Midodrine in end-stage heart failure.
Topics: Heart Failure; Hospitalization; Humans; Hypotension; Male; Midodrine; Vasoconstrictor Agents | 2023 |
Case report: severe myoclonus associated with oral midodrine treatment for hypotension.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Female; Humans; Hypotension; Middle Aged | 2020 |
Midodrine administration during critical illness: fixed-dose or titrate to response?
Topics: Critical Illness; Humans; Hypotension; Intensive Care Units; Midodrine; Vasoconstrictor Agents | 2021 |
High-dose midodrine is not effective for treatment of persistent hypotension in the intensive care unit.
Topics: Humans; Hypotension; Intensive Care Units; Midodrine; Vasoconstrictor Agents | 2021 |
[Arterial hypotension: behind the scenes].
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Droxidopa; Humans; Hypotension; Hypoten | 2018 |
The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension.
Topics: Aged; Aged, 80 and over; Blood Pressure; Female; Follow-Up Studies; Hospitalization; Humans; Hypoten | 2018 |
Intradialytic Hypotension: Is Midodrine the Answer?
Topics: Humans; Hypotension; Midodrine; Renal Dialysis | 2018 |
Pediatric intradialytic hypotension: recommendations from the Pediatric Continuous Renal Replacement Therapy (PCRRT) Workgroup.
Topics: Age Factors; Blood Pressure; Blood Pressure Determination; Child; Consensus; Continuous Renal Replac | 2019 |
Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study.
Topics: Aged; Female; Humans; Hypotension; Intensive Care Units; Length of Stay; Male; Middle Aged; Midodrin | 2019 |
Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Epoprostenol; Humans; Hypotension; Kidney | 2019 |
Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions.
Topics: Administration, Oral; Aged; Female; Humans; Hypotension; Infusions, Intravenous; Intensive Care Unit | 2013 |
Dialysate temperature adjustment as an effective treatment for baroreflex failure syndrome in hemodialysis patient.
Topics: Aged; Baroreflex; Carotid Sinus; Cold Temperature; Dialysis Solutions; Dizziness; Droxidopa; Enteral | 2014 |
Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications After Kidney Transplantation.
Topics: Adolescent; Adult; Aged; Blood Pressure; Delayed Graft Function; Female; Genetic Markers; Graft Surv | 2016 |
The value of sequential dialysis, mannitol and midodrine in managing children prone to dialysis failure.
Topics: Adolescent; Child; Female; Humans; Hypotension; Male; Mannitol; Midodrine; Renal Dialysis; Treatment | 2009 |
Chronic hypotension and modulation of autonomic cardiovascular regulation.
Topics: Adrenergic alpha-Agonists; Autonomic Nervous System; Baroreflex; Cardiovascular Physiological Phenom | 2009 |
Hemodialysis in hypotensive heart failure using midodrine.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Blood Pressure; Female; Heart Failure; Humans; H | 2009 |
Refractory hypotension due to Rogaine® (minoxidil) ingestion managed with midodrine.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Blood Pressure; Emergency Service, Hospi | 2011 |
Refractory hypotension after bilateral nephrectomies in a Denys-Drash patient with phenylketonuria.
Topics: Adrenergic alpha-1 Receptor Agonists; Denys-Drash Syndrome; Female; Humans; Hypotension; Infant; Inf | 2013 |
Midodrine, an alternative to intravenous vasopressor therapy after spinal surgery.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Humans; Hypotension; Infusions, Intravenous; | 2002 |
Midodrine improves chronic hypotension in hemodialysis patients.
Topics: Adrenergic alpha-Agonists; Adult; Autonomic Nervous System; Chronic Disease; Female; Hemodynamics; H | 2003 |
Postprandial hypotension treated with acarbose in a patient with type 1 diabetes mellitus.
Topics: Acarbose; Adrenergic alpha-Agonists; Anti-Inflammatory Agents; Blood Pressure; Diabetes Mellitus, Ty | 2004 |
Successful treatment of hypotension associated with stunned myocardium with oral midodrine therapy.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Aged; Humans; Hypotension; Male; Middle Aged; Midod | 2005 |
Effect of mineralocorticoids on interdialytic weight gain in hemodialysis patients with perdialytic hypotension.
Topics: Adrenergic alpha-Agonists; Aged; Anti-Inflammatory Agents; Blood Pressure; Drug Resistance; Female; | 2005 |
Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiotonic Agents; Carotid Stenosis; Dopamine; Femal | 2008 |
Treatment of postprandial hypotension with selective alpha 1 and beta 1 adrenergic agonists.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aged; Blood Pressure; Cardiac Output; Drug Ther | 1993 |
Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension.
Topics: Adolescent; Adrenergic alpha-Agonists; Half-Life; Humans; Hypotension; Kidney Failure, Chronic; Male | 1996 |
Midodrine hydrochloride in patients on hemodialysis with chronic hypotension.
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Combined Modality Therapy; Drug Evaluation; Fema | 1996 |
Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients?
Topics: Administration, Oral; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Blood Pressure; Diastole; | 1997 |
Midodrine in intradialytic hypotension.
Topics: Clinical Trials as Topic; Humans; Hypotension; Midodrine; Renal Dialysis; Treatment Outcome; Vasocon | 1999 |
[Midodrine (Gutron) treatment of permanent arterial hypotension in a chronic hemodialysis patient].
Topics: Adrenergic alpha-Agonists; Chronic Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Hy | 2000 |
Use of midodrine (Gutron) to treat permanent hypotension in a chronic hemodialysis patient.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Humans; Hypotension; Kidney Failure, Chronic; Male | 2001 |
[Treatment of hypotension in general practice with Gutron].
Topics: Adult; Drug Evaluation; Ethanolamines; Family Practice; Female; Humans; Hypotension; Male; Middle Ag | 1975 |
[Tolerance tests of alpha-sympathomimetic agent, Gutron].
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Blood Coagulation; Drug Evaluation; Drug Toleran | 1976 |
Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Capillary Permeability; Cats; Decerebrate State; | 1976 |
[Diagnosis and therapy of hypotensive circulatory disorders in general practice. Experiences with Gutron using the Thulesius-diagram for diagnosis and supervision of therapy].
Topics: Adult; Ethanolamines; Female; Humans; Hypotension; Hypotension, Orthostatic; Male; Methods; Midodrin | 1979 |
Anti-hypotensive effects of M6434, an orally active alpha 1-adrenoceptor agonist, in rats.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Animals; Blood Pressure; Decerebrate State; Dihydro | 1992 |
A case of vasovagal syncope with convulsions--the effects of midodrine hydrochloride.
Topics: Adult; Blood Pressure; Bradycardia; Female; Humans; Hypotension; Midodrine; Seizures; Syncope; Vagus | 1992 |